RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Supernus Pharmaceuticals Stock

Supernus Pharmaceuticals P/E 2024

Supernus Pharmaceuticals P/E

15.65

Ticker

SUPN

ISIN

US8684591089

WKN

A1JX3U

As of Aug 24, 2024, Supernus Pharmaceuticals's P/E ratio was 15.65, a 1,025.9% change from the 1.39 P/E ratio recorded in the previous year.

The Supernus Pharmaceuticals P/E history

Supernus Pharmaceuticals Aktienanalyse

What does Supernus Pharmaceuticals do?

Supernus Pharmaceuticals Inc is an American company specializing in the development, manufacturing, and marketing of pharmaceuticals. The company was founded in 2005 and is headquartered in Rockville, Maryland. Initially, Supernus Pharmaceuticals focused on developing medications for neurological disorders such as epilepsy and ADHD. However, the company has since expanded into other areas of indication such as migraine and Parkinson's disease. The top products of Supernus Pharmaceuticals are the two epilepsy medications, Oxtellar XR and Trokendi XR, both based on a patented technology called "Troxerutin Enriched Osmotic Delivery System" (TREOS). This technology allows for timed release of the active ingredient, resulting in longer duration of action and improved tolerability. Both products are approved in the United States and have proven to be effective and well-tolerated. In addition to Oxtellar XR and Trokendi XR, Supernus Pharmaceuticals has launched other products on the market, including XADAGO for the treatment of Parkinson's disease and Qudexy XR for the treatment of migraine. The company also has a number of compounds in the pipeline currently in various stages of development. The business model of Supernus Pharmaceuticals is based on the development of proprietary technologies and the marketing of novel pharmaceuticals. The company works closely with industry and scientific partners to find innovative solutions to medical challenges. For Supernus Pharmaceuticals, quality is a central component of its business model. The company adheres to strict regulatory requirements and employs modern manufacturing techniques to ensure the highest standards in pharmaceutical production. Additionally, the company maintains close relationships with healthcare providers and patient organizations to ensure that its products meet the needs of patients. Supernus Pharmaceuticals also pursues a robust growth strategy based on exploring new markets and expanding its product portfolio. The company aims to expand its pipeline and develop new technologies to improve the treatment of neurological disorders and promote patient health worldwide. Overall, Supernus Pharmaceuticals is an innovative company distinguished by its commitment to quality and focus on novel solutions in the pharmaceutical industry. The company has established itself as a leading provider of medications for neurological disorders and strives to expand its position in this growing market. Supernus Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Supernus Pharmaceuticals's P/E Ratio

The Price to Earnings (P/E) Ratio of Supernus Pharmaceuticals is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Supernus Pharmaceuticals's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Supernus Pharmaceuticals is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Supernus Pharmaceuticals’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Supernus Pharmaceuticals stock

What is the price-to-earnings ratio of Supernus Pharmaceuticals?

The price-earnings ratio of Supernus Pharmaceuticals is currently 15.65.

How has the price-earnings ratio of Supernus Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Supernus Pharmaceuticals has increased by 1,025.9% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Supernus Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Supernus Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Supernus Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Supernus Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Supernus Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Supernus Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Supernus Pharmaceuticals?

Some factors that influence the price-earnings ratio of Supernus Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Supernus Pharmaceuticals pay?

Over the past 12 months, Supernus Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Supernus Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Supernus Pharmaceuticals?

The current dividend yield of Supernus Pharmaceuticals is .

When does Supernus Pharmaceuticals pay dividends?

Supernus Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Supernus Pharmaceuticals?

Supernus Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Supernus Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Supernus Pharmaceuticals located?

Supernus Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Supernus Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Supernus Pharmaceuticals from 8/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/24/2024.

When did Supernus Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/24/2024.

What was the dividend of Supernus Pharmaceuticals in the year 2023?

In the year 2023, Supernus Pharmaceuticals distributed 0 USD as dividends.

In which currency does Supernus Pharmaceuticals pay out the dividend?

The dividends of Supernus Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Supernus Pharmaceuticals

Our stock analysis for Supernus Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Supernus Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.